Strong Profitability and ROE
Adjusted operating income of $172 million ($1.21 per diluted share); adjusted operating return on equity ~13% (12.9% reported by CFO), up from $1.10 per diluted share year-over-year.
Robust New Insurance Written and Year-over-Year Growth
New insurance written (NIW) of $13 billion in Q1; NIW down 11% sequentially but up 30% year-over-year, supporting business growth and market engagement.
Large Insurance-in-Force and Persistency Support
Primary insurance-in-force of $272 billion (up ~$4 billion, ~2% year-over-year); persistency remained elevated at 80% (flat sequentially), with 58% of loans in the book having rates below 6%, supporting long-term persistency.
Strong Capital, Liquidity and Shareholder Returns
PMIERs sufficiency ratio of 162% (~$1.9 billion above requirement); returned $123 million to shareholders in Q1 (buybacks + dividends); Board approved a 14% dividend increase (from $0.21 to $0.24); 2026 capital return target remains ~ $500 million.
Credit Performance and Reserve Release
Total delinquencies down 1% sequentially; new delinquencies of 13,600 (down from 13,700); cure activity strong (cures described as up 13% in prepared remarks and cure rate up 3 percentage points to 54%), driving a net reserve release of $39 million and a maintained claim rate on new delinquencies of 8%.
Investment Income and Yield Improvement
Investment income of $71 million, up $2 million sequentially (+3%) and up $8 million year-over-year (+12%); new-money investment yield ~5% and average portfolio book yield 4.5%, supporting overall income.
Expense Management
Operating expenses of $49 million and an expense ratio of 20% in Q1, down from $59 million and 24% in Q4 2025; reaffirmed full-year 2026 operating expense guidance of $215M–$220M (ex-reorg).